Presently, there is a prevailing belief that individuals afflicted with conditions such as rheumatoid arthritis (RA), inflammatory bowel disease, PsO, and PsA may encounter an increased occurrence of skin cancer when undergoing treatment with biologics, such as tumor necrosis factor (TNF)-alpha inhibitors. This evidence concerns the gene TNF and rheumatoid arthritis.